Literature DB >> 1698160

The N-terminal 1-16, but not C-terminal 17-29, galanin fragment affects the flexor reflex in rats.

X J Xu1, Z Wiesenfeld-Hallin, G Fisone, T Bartfai, T Hökfelt.   

Abstract

The biological activity of two galanin (GAL) fragments, GAL-(1-16) and GAL-(17-29), was tested in vivo by using a spinal nociceptive flexor reflex model in the rat. Intrathecal (i.t.) GAL-(1-16) had a similar biphasic effect on the flexor reflex, with facilitation at lower doses and facilitation followed by depression at higher doses, as the full length peptide GAL-(1-29). GAL-(1-16) also effectively depressed the facilitation of the flexor reflex caused by i.t. substance P (SP) or C-fiber conditioning stimulation (CS) and potentiated the depressive effect of i.t. morphine on the reflex, both actions that have been reported earlier with GAL-(1-29). In contrast, i.t. GAL-(17-29), even at high doses, did not induce changes in the amplitude of the flexor reflex, nor did it interact with the effects of i.t. SP, morphine or C-fiber CS. It is concluded that the N-terminal portion of GAL-(1-29) is critical for the biological activity of the intact peptide in the dorsal horn of the rat spinal cord. The similarity between the effects of GAL-(1-16) and GAL-(1-29) indicates that they probably act on the same GAL receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698160     DOI: 10.1016/0014-2999(90)90502-w

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Prediction of conformation of rat galanin in the presence and absence of water with the use of Monte Carlo methods and the ECEPP/3 force field.

Authors:  A Liwo; S Ołdziej; J Ciarkowski; G Kupryszewski; M R Pincus; R J Wawak; S Rackovsky; H A Scheraga
Journal:  J Protein Chem       Date:  1994-05

2.  Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide.

Authors:  W E Schmidt; H Kratzin; K Eckart; D Drevs; G Mundkowski; A Clemens; S Katsoulis; H Schäfer; B Gallwitz; W Creutzfeldt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  Intracerebroventricular galanin and N-terminal galanin fragment enhance the morphine-induced analgesia in the rat.

Authors:  B Przewłocka; H Machelska; P Rekowski; G Kupryszewski; R Przewłocki
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 4.  Galanin--a neuropeptide with inhibitory actions.

Authors:  K Kask; U Langel; T Bartfai
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 5.  Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer's disease.

Authors:  M P McDonald; J N Crawley
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

6.  A short estrogen-responsive N-terminal galanin homologue found in rat brain and gut with antiserum raised against rat galanin(1-16).

Authors:  Susanne Hilke; Tomas Hökfelt; Elvar Theodorsson
Journal:  Neurochem Res       Date:  2006-04-04       Impact factor: 3.996

7.  Characterization of a high-affinity galanin receptor in the rat anterior pituitary: absence of biological effect and reduced membrane binding of the antagonist M15 differentiate it from the brain/gut receptor.

Authors:  D Wynick; D M Smith; M Ghatei; K Akinsanya; R Bhogal; P Purkiss; P Byfield; N Yanaihara; S R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  New high affinity peptide antagonists to the spinal galanin receptor.

Authors:  X J Xu; Z Wiesenfeld-Hallin; U Langel; K Bedecs; T Bartfai
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

9.  Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.

Authors:  U Kahl; U Langel; T Bartfai; L Grundemar
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

10.  Spinal antinociception by morphine in rats is antagonised by galanin receptor antagonists.

Authors:  W Reimann; W Englberger; E Friderichs; N Selve; B Wilffert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.